Quick Answer
Edgewise Therapeutics, Inc. reported Stockholders Equity of $522.26 million for the year ending 2025.
- Edgewise Therapeutics, Inc. showed an increase of +13.7% in Stockholders Equity from 2024 to 2025.
- This data is from Edgewise Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$19.98 million | Q2 2020: -$23.76 million | Q3 2020: -$27.27 million | Q1 2021: $306.39 million | Q2 2021: $296.75 million | Q3 2021: $285.40 million | Q1 2022: $260.36 million | Q2 2022: $246.36 million | Q3 2022: $361.40 million | Q1 2023: $328.84 million | Q2 2023: $311.46 million | Q3 2023: $290.43 million | Q1 2024: $534.94 million | Q2 2024: $510.47 million | Q3 2024: $488.88 million | Q1 2025: $429.72 million | Q2 2025: $589.07 million | Q3 2025: $558.65 million.
- Over the full 7 years of available data (2019 to 2025), Edgewise Therapeutics, Inc.'s Stockholders Equity has grown by 3,198.9%.
- Historical annual values: Fiscal year 2025: $522.26 million | Fiscal year 2024: $459.22 million | Fiscal year 2023: $318.83 million | Fiscal year 2022: $346.72 million | Fiscal year 2021: $274.38 million | Fiscal year 2020: -$33.42 million | Fiscal year 2019: -$16.85 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: